Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.
Related Posts
Golden Globes 2026 Full Winners List
- nationalpillarnews
- January 12, 2026
- 0
One Battle After Another is leading the race with nine nominations
Radhika Apte wants to change working hours in film industry, had ‘multiple arguments for refusing to do long shifts’
- nationalpillarnews
- January 14, 2026
- 0
Radhika Apte talked about her non-negotiables when signing a script. She said that she would appreciate a five-day work week and a 12-hour shift.
Time for government, companies to adopt artificial intelligence: Deloitte India
- nationalpillarnews
- January 8, 2026
- 0
“Indian companies need to re-skill, train, and acquire more relevant talent, if they are to successfully integrate AI technologies. Most importantly, they should be willing […]